STOCK TITAN

Blueprint Medicines Corporation - BPMC STOCK NEWS

Welcome to our dedicated page for Blueprint Medicines Corporation news (Ticker: BPMC), a resource for investors and traders seeking the latest updates and insights on Blueprint Medicines Corporation stock.

Blueprint Medicines Corporation (Nasdaq: BPMC) is a leading biopharmaceutical company focused on developing highly selective and potent kinase therapies to treat genomically defined diseases. With a deep understanding of the genetic blueprint of cancer and other kinase-driven diseases, Blueprint Medicines leverages its proprietary chemical compounds to craft therapies for new and challenging targets.

Blueprint Medicines boasts a robust pipeline, spearheaded by AYVAKIT (avapritinib), a drug designed for the treatment of systemic mastocytosis (SM) and other related disorders. AYVAKIT has secured approvals in the U.S. and Europe, marking significant strides in offering therapeutic solutions for patients with advanced SM, indolent systemic mastocytosis (ISM), and highly specific mutations in gastrointestinal stromal tumors.

Among its promising pipeline, Blueprint Medicines is developing several innovative candidates, including BLU-808, aimed at treating mast cell disorders like chronic urticaria and sleep disruptions, and BLU-222, focusing on breast cancer treatment. The company consistently demonstrates its commitment to transforming patient care through groundbreaking research and development.

Recent achievements highlight the company's growth trajectory. In Q3 2023, Blueprint reported strong revenue growth following AYVAKIT's successful launch for ISM, supported by its favorable clinical profile. The European Medicines Agency has recently given a positive opinion for AYVAKYT, extending its indication to ISM patients, reflecting the company's continued expansion in global markets.

Blueprint Medicines remains dedicated to advancing its clinical pipeline, optimizing operational efficiency, and securing strategic partnerships to harness market potential. The company is committed to delivering innovative therapies, offering hope and improved outcomes for patients worldwide.

  • Core Business: Development of selective kinase therapies for genomically defined diseases.
  • Key Products: AYVAKIT/AYVAKYT for systemic mastocytosis and gastrointestinal stromal tumors.
  • Current Projects: Development of BLU-808, BLU-222, and other therapies targeting mast cell disorders and various cancers.
  • Recent Achievements: Strong revenue growth, positive EMA opinion, expansion in Europe.
  • Partnerships: Collaborations with global healthcare agencies and ongoing clinical trials.
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced the grant of stock options and restricted stock units (RSUs) to five new employees effective November 1, 2020. The total includes 16,513 stock options and 8,255 RSUs, awarded under the 2020 Inducement Plan. The options have an exercise price of $102.28, matching the stock's closing price on October 31, 2020. Options and RSUs will vest incrementally over time, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ:BPMC) reported strong Q3 2020 financial results, achieving $745.1 million in total revenues. The net income surged to $634.0 million, or $11.16 per diluted share, compared to a net loss of $94.3 million in Q3 2019. Key product revenue included $6.1 million from AYVAKIT and $0.2 million from GAVRETO. The company expects significant growth with the upcoming supplemental NDA for AYVAKIT and the potential U.S. approval of GAVRETO for RET-altered thyroid cancers by February 2021, strengthening its market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
-
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast on October 29, 2020 at 8:30 a.m. ET to discuss its third-quarter 2020 financial results and provide a corporate update. Investors can access the call by dialing (855) 728-4793 domestically or (503) 343-6666 internationally, using conference ID 2995408. A webcast will be available post-call on the Blueprint Medicines website. The company specializes in precision therapies targeting genomically defined cancers, rare diseases, and cancer immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
conferences earnings
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced on October 2, 2020, that it granted non-qualified stock options and restricted stock units (RSUs) to five new employees, effective October 1, 2020. The total grants comprise 77,118 stock options and 38,557 RSUs, including a significant award to the new President of Research & Development, Fouad Namouni, M.D. The options have an exercise price of $93.93, aligning with the stock's closing price on the grant date. These grants are part of the 2020 Inducement Plan designed to attract new talent in alignment with NASDAQ listing rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
none
-
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced that the European Commission has granted conditional marketing authorization for AYVAKYT® (avapritinib) to treat adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with the PDGFRA D842V mutation. This marks the first approved therapy in Europe targeting this specific mutation. AYVAKYT showed a remarkable 95% overall response rate in the NAVIGATOR trial. The company plans to launch the drug initially in Germany, with subsequent launches in other countries based on local reimbursement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) reported positive top-line results from Phase 1 EXPLORER and Phase 2 PATHFINDER trials of AYVAKIT™ (avapritinib) in advanced systemic mastocytosis (SM). The trials demonstrated significant reductions in mast cell burden and high overall response rates. AYVAKIT was well-tolerated, showing improved safety at a 200 mg once daily dose. Blueprint plans to submit a supplemental new drug application to the FDA in Q4 2020, aiming to provide a transformative treatment option for patients with advanced SM.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.03%
Tags
none
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced promising results from the ARROW clinical trial for GAVRETO™ (pralsetinib) in patients with RET-mutant medullary thyroid cancer. The trial demonstrated a 60% overall response rate in previously treated patients and 74% in treatment-naïve patients. The drug showed robust safety and tolerability, with most adverse events being Grade 1 or 2. GAVRETO is under FDA review for use in advanced RET-mutant MTC, further supported by the updated NCCN guidelines. The trial results were presented at the ESMO Virtual Congress 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced promising preclinical data for BLU-945, a precision therapy targeting osimertinib-resistant EGFR-mutated non-small cell lung cancer (NSCLC). The data, presented at the ESMO Virtual Congress 2020, show that BLU-945 effectively inhibited triple-mutant EGFR, demonstrating over 900-fold selectivity compared to wild-type EGFR and robust anti-tumor activity in various lung cancer models. Blueprint plans to initiate a Phase 1 trial in early 2021 and is actively pursuing additional candidates to address the urgent need for new therapies in this patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
-
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ:BPMC) will have its CEO, Jeff Albers, participate in a virtual fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on September 16, 2020, at 12:30 p.m. ET. This event focuses on the company's advancements in precision therapies for genomically defined cancers and rare diseases. A live webcast of the presentation can be accessed through the Investors & Media section of their website, with a replay available for 30 days. Blueprint Medicines is known for its innovative approach to developing targeted therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
conferences
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) has received FDA approval for GAVRETO™ (pralsetinib), targeting adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). This approval was based on the ARROW clinical trial, demonstrating a 57% overall response rate in previously treated patients and 70% in treatment-naïve patients. GAVRETO is a once-daily oral therapy that could significantly enhance treatment options for this patient group. The product will be co-commercialized with Roche in the U.S., and rapid patient access is planned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags

FAQ

What is the current stock price of Blueprint Medicines Corporation (BPMC)?

The current stock price of Blueprint Medicines Corporation (BPMC) is $95.97 as of December 6, 2024.

What is the market cap of Blueprint Medicines Corporation (BPMC)?

The market cap of Blueprint Medicines Corporation (BPMC) is approximately 6.0B.

What is Blueprint Medicines Corporation's primary focus?

Blueprint Medicines Corporation focuses on developing highly selective and potent kinase therapies for the treatment of genomically defined diseases.

What is AYVAKIT?

AYVAKIT (avapritinib) is a kinase inhibitor approved for the treatment of various forms of systemic mastocytosis (SM) and specific mutations in gastrointestinal stromal tumors.

What recent achievements has Blueprint Medicines made?

Recent achievements include strong revenue growth following AYVAKIT’s launch for indolent systemic mastocytosis (ISM) and a positive opinion from the European Medicines Agency for expanding AYVAKYT’s indications.

What are some key products in Blueprint Medicines' pipeline?

Key products in the pipeline include BLU-808 for mast cell disorders and BLU-222 for breast cancer treatment.

What sets Blueprint Medicines apart in drug development?

Blueprint Medicines stands out for its deep understanding of genetic drivers of disease and its proprietary library of novel chemical compounds, enabling the creation of kinase therapies targeting difficult-to-drug genomic subsets.

How does Blueprint Medicines contribute to patient care?

By focusing on genomically defined subsets of patients, Blueprint Medicines aims to create more efficient clinical development paths, improving the likelihood of successful outcomes and better patient care.

Where can I learn more about Blueprint Medicines’ clinical trials?

Information about ongoing or planned clinical trials can be found at blueprintclinicaltrials.com or clinicaltrials.gov.

How can I contact Blueprint Medicines for more information?

For more information, visit their website at www.BlueprintMedicines.com, or follow them on Twitter (@BlueprintMeds) and LinkedIn.

What are the company’s future plans for AYVAKIT?

Blueprint Medicines plans to continue expanding AYVAKIT's indications and market reach, particularly in Europe and the U.S., driven by its strong clinical profile and patient demand.

What are the primary therapeutic areas Blueprint Medicines is focusing on?

Blueprint Medicines is focusing on allergy/inflammation and oncology/hematology, with a strategic investment in therapeutic areas leveraging their core expertise and business infrastructure.

Blueprint Medicines Corporation

Nasdaq:BPMC

BPMC Rankings

BPMC Stock Data

6.05B
62.85M
0.9%
104.77%
6.16%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE